Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy : A retrospective study.
High-dose radiation therapy
Local ablative therapy
Non-invasive oncologic intervention
Precision Oncology
Primary liver cancer
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
10
12
2023
accepted:
17
03
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
Hepatocellular carcinoma (HCC) poses a unique challenge due to its predilection for developing on compromised livers, often limiting surgical options. Stereotactic body radiotherapy (SBRT) has emerged as a promising local treatment modality for HCC. This study aims to assess the effectiveness of SBRT in HCC patients not suitable for surgery, focusing on local control, optimal radiation dosing, and prognostic factors. In this retrospective analysis, 52 HCC patients treated with SBRT were examined. The study assessed local control, progression-free survival (PFS), and overall survival (OS) while conducting dosimetric analyses. The relationship between mean liver dose and Child-Pugh score (CPS) progression was also explored. SBRT demonstrated 93.4% freedom from local progression (FFLP) at 12 months. Notably, a near minimum dose (D98%) below 61 Gy as an equivalent dose in 2‑Gy fractions with α/β 10 Gy (EQD2 SBRT offers a compelling option for achieving high local control and promising survival outcomes in HCC. The study supports a radiation dose range of 61-73.1 Gy, coupled with a mean liver dose under 12.6-12.8 Gy as EQD2, to achieve favorable FFLP rates, with acceptable toxicity rates.
Identifiants
pubmed: 38689147
doi: 10.1007/s00066-024-02235-5
pii: 10.1007/s00066-024-02235-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
pubmed: 33538338
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576
doi: 10.1053/j.gastro.2007.04.061
pubmed: 17570226
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y et al (2021) Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). Hepatol Res 51(4):355–405
doi: 10.1111/hepr.13612
pubmed: 33382910
Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol 196(5):417–420. https://doi.org/10.1007/s00066-020-01603-1
doi: 10.1007/s00066-020-01603-1
pubmed: 32211940
pmcid: 7182610
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5
doi: 10.1016/S0140-6736(18)32487-5
pubmed: 30982687
Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL et al (2017) Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer. Strahlenther Onkol 193(6):433–443. https://doi.org/10.1007/s00066-017-1099-8
doi: 10.1007/s00066-017-1099-8
pubmed: 28138949
Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639
doi: 10.1200/JCO.2012.44.1659
pubmed: 23547075
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJM, McRae SE, Widder J, Feng L et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6):630–637
doi: 10.1016/S1470-2045(15)70168-3
pubmed: 25981812
pmcid: 4489408
Mohamed AA, Goncalves M, Singh BP, Tometten M, Rashad A, Hölzle F, Hackenberg S, Eble M (2024) Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02180-9
doi: 10.1007/s00066-023-02180-9
pubmed: 38315236
Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K (2019) Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. https://doi.org/10.1002/hep.30591
doi: 10.1002/hep.30591
pubmed: 30805950
Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, Kenjo M, Murakami Y, Honda Y, Kakizawa H et al (2015) Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 45(4):378–386
doi: 10.1111/hepr.12359
pubmed: 24849379
Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O (2019) Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B–C hepatocellular carcinoma. Strahlenther Onkol 195(3):254–264. https://doi.org/10.1007/s00066-018-1391-2
doi: 10.1007/s00066-018-1391-2
pubmed: 30413833
Jacob R, Turley F, Redden DT, Saddekni S, Aal AKA, Keene K, Yang E, Zarzour J, Bolus D, Smith JK et al (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. https://www.hpbonline.org/article/S1365-182X (15)31172-2/pdf. Accessed 27 July 2019
Shin HS, Hwan Lee S, Jun BG, Kim HS, Kang SH, Park JY, Choi SI, Cheon GJ, Kim YD, Yoo JJ et al (2022) Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 34(11):1187–1194
doi: 10.1097/MEG.0000000000002442
pubmed: 36170689
Wong TCL, Lee VHF, Law ALY, Pang HH, Lam KO, Lau V, Cui TY, Fong ASY, Lee SWM, Wong ECY et al (2021) Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology 74(5):2580
doi: 10.1002/hep.31992
pubmed: 34091914
Lencioni R, Llovet JM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. https://doi.org/10.1055/s-0030-1247132 . Accessed 4 Jan 2020
Benson R, Madan R, Kilambi R, Chander S (2016) Radiation induced liver disease: a clinical update. J Egypt Natl Canc Inst 28(1):7–11
doi: 10.1016/j.jnci.2015.08.001
pubmed: 26300327
Chapman TR, Bowen SR, Schaub SK, Yeung RH, Kwan SW, Park JO, Yu L, Harris WP, Johnson GE, Liou IW et al (2018) Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol 8(3):157–166
doi: 10.1016/j.prro.2017.10.013
pubmed: 29426691
Son SH, Jang HS, Lee H, Choi BO, Kang YN, Jang JW, Yoon SK, Kay CS (2013) Determination of the α/β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat Oncol 8(1):61
doi: 10.1186/1748-717X-8-61
pubmed: 23497395
pmcid: 3641977
Lawremce TS, Dworzanin LM, Walker-Andrews SC, Andrews JC, Ten Haken RK, Wollmer IS, Lichter AS, Ensminger WD (1991) Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 20(3):555–561
doi: 10.1016/0360-3016(91)90069-G
Durand-Labrunie J, Baumann A (2020) Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. https://www.sciencedirect.com/science/article/pii/S0360301619345122 . Accessed 3 Oct 2023
Il JW, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, Cho EH, Choi CW, Kim KS, Hwang S et al (2020) A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. Cancer 126(2):363–372
doi: 10.1002/cncr.32502
Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S et al (2021) Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatol Res 51(4):461–471
doi: 10.1111/hepr.13595
pubmed: 33217113
Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34(5):452–459. https://doi.org/10.1200/JCO.2015.61.4925
doi: 10.1200/JCO.2015.61.4925
pubmed: 26628466
Kim N, Cheng J, Jung I, Liang JD, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R et al (2020) tereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol 73(1):121–129
doi: 10.1016/j.jhep.2020.03.005
pubmed: 32165253
Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND et al (2018) Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 100(1):122–130
doi: 10.1016/j.ijrobp.2017.09.001
pubmed: 29066120
Méndez Romero A, van der Holt B, Willemssen FEJA, de Man RA, Heijmen BJM, Habraken S, Westerveld H, van Delden OM, Klümpen HJ, Tjwa ETTL et al (2023) Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial). Int J Radiat Oncol Biol Phys 117(1):45–52
doi: 10.1016/j.ijrobp.2023.03.064
pubmed: 37037359
Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D et al (2022) Stereotactic radiotherapy after incomplete transarterial (chemo-) embolization (TAE\TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360). Curr Oncol 29(11):8802–8813
doi: 10.3390/curroncol29110692
pubmed: 36421345
pmcid: 9689962
Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N, Koundurdjieva I, Kirste S, Neeff HP, Goetz C et al (2021) Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical efficacy study). Front Oncol. https://doi.org/10.3389/fonc.2021.653141
doi: 10.3389/fonc.2021.653141
pubmed: 34055636
pmcid: 8162208
Ohri N, Tomé WA, Méndez Romero A, Miften M, Ten Haken RK, Dawson LA, Grimm J, Yorke E, Jackson A (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188–195
doi: 10.1016/j.ijrobp.2017.12.288
pubmed: 29395629
Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ et al (2013) High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 8(1):1–12. https://doi.org/10.1186/1748-717X-8-250
doi: 10.1186/1748-717X-8-250
Su TS, Liu QH, Zhu XF, Liang P, Liang SX, Lai L, Zhou Y, Huang Y, Cheng T, Li LQ (2021) Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. Radiat Oncol 16(1)
Dawson LA, Normolle D, Balter JM, Mcginn CJ, Lawrence TS, Ten Haken RK (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model
doi: 10.1016/S0360-3016(02)02846-8
Li JX, Zhang RJ, Qiu MQ, Yan LY, He ML, Long MY, Zhong JH, Lu HY, Zhou HM, Xiang B‑D et al (2023) Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade B patients with locally advanced hepatocellular carcinoma. Radiat Oncol 18(1):48
doi: 10.1186/s13014-023-02232-5
pubmed: 36890592
pmcid: 9993633
Bae S, Park H, Yoon W et al (2019) Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with Child-Pugh classification B in Korea (KROG 16-05). https://synapse.koreamed.org/articles/1153809 . Accessed 6 Oct 2023
Sharma D, Thaper D, Kamal R, Yadav HP (2023) Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients. Strahlenther Onkol 199(9):838–846. https://doi.org/10.1007/s00066-023-02065-x
doi: 10.1007/s00066-023-02065-x
pubmed: 36932236
Dawson LA, Winter KA, Knox JJ et al (2023) NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). J Clin Oncol 41(4):489. https://doi.org/10.1200/JCO.2023.41.4_suppl.489
doi: 10.1200/JCO.2023.41.4_suppl.489
Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F et al (2023) Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 115(1):202–213
doi: 10.1016/j.ijrobp.2022.09.052
pubmed: 36108891
Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, Fritsch R, Brass V, Maruschke L, Neeff HP et al (2019) Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol 195(3):246–253. https://doi.org/10.1007/s00066-018-1385-0
doi: 10.1007/s00066-018-1385-0
pubmed: 30353350